Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

PHASE4RecruitingINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Clonorchiasis
Interventions
DRUG

Albendazole

Participants receive albendazole tablets orally at a total daily dose of 10 mg/kg for 7 consecutive days. The daily dose will be administered in two divided doses. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.

DRUG

Tribendimidine

Patients receive tribendimidine enteric-coated tablets orally at 0.4 g once daily (QD) for 3 consecutive days.

DRUG

praziquantel

Participants receive praziquantel tablets orally at 25 mg/kg per dose, three times daily (TID) for 2 consecutive days. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.

Trial Locations (2)

530021

NOT_YET_RECRUITING

People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

All Listed Sponsors
collaborator

People's Hospital of Guangxi Zhuang Autonomous Region

OTHER

collaborator

Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control

OTHER_GOV

lead

First Affiliated Hospital of Guangxi Medical University

OTHER